A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition

Wollenberg, Andreas; Moosmann, Nicolas; Klein, Elisabeth; Katzer, K.

doi:10.1111/j.1600-0625.2008.00715.x

Cited by 39 publications

(28 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, topical mometason furoate was the only therapy that resulted in a complete resolution of all rash symptoms in one patient. Yet, it must be noted that statistical significance is highly dependent on the number of patients included in each group, and because the ERSS system was designed with a non-linear affected-area scale emphasizing minor variations in mild patients with face involvement only [26].…”

Section: Discussionmentioning

confidence: 99%

“…Rash severity was assessed applying the EGFRIinduced rash severity score (ERSS or WoMoScore), a skinspecific scoring system introduced in 2008 [26]. Briefly, the ERSS is a combined score of the severity of five different aspects of the EGFRI-rash (color of erythema, distribution of erythema, papulation, pustulation and scaling/ crusts), combined with a score based on the extent of affected facial area and the total body area involved.…”

Section: Assessment Of Rash Severitymentioning

confidence: 99%

“…Briefly, the ERSS is a combined score of the severity of five different aspects of the EGFRI-rash (color of erythema, distribution of erythema, papulation, pustulation and scaling/ crusts), combined with a score based on the extent of affected facial area and the total body area involved. ERSSs range from 0 (no skin affection), 1 to 20 (mild), between 20 and 40 (moderate), up to scores exceeding 40 points, indicating severe cases (Figure 1) [26].…”

Section: Assessment Of Rash Severitymentioning

confidence: 99%

See 2 more Smart Citations

Management of EGFR-inhibitor associated rash: A retrospective study in 49 patients

et al. 2012

Self Cite

View full text Add to dashboard Cite

Background: In recent years inhibitors directed against the epidermal growth factor receptor (EGFR) have evolved as effective targeting cancer drugs. Characteristic papulopustular exanthemas, often described as acneiform rashes, are the most frequent adverse effect associated with this class of novel cancer drugs and develop in > 90% of patients. Notably, the rash may significantly compromise the patients' quality of life, thereby potentially leading to incompliance as well as dose reduction or even termination of the anti-EGFR therapy. Yet, an effective dermatologic management of cutaneous adverse effects can be achieved. Whereas various case reports, case series or expert opinions on the management of EGFR-inhibitor (EGFRI) induced rashes have been published, data on systematic management studies are sparse.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Assessment Of Rash Severitymentioning

confidence: 99%

Section: Assessment Of Rash Severitymentioning

confidence: 99%

See 1 more Smart Citation

Management of EGFR-inhibitor associated rash: A retrospective study in 49 patients

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…These drugs include glycocorticoids, anabolic steroids, danazol, testosterone, progestogens, thyroid hormones, halogenated derivatives (iodine, bromine, fluoride and chlorine), vitamin B12, antibiotics (tetracycline and streptomycin), antituberculosis drugs (isoniazid), lithium carbonate, antiepileptic drugs (phenobarbital and hydantoin derivatives), cyclosporin A, antimycotics, gold salts, isotretinoin, clofazimine and epidermal growth factor receptor inhibitors (cetuximab, gefitinib and erlotinib), among others. [12][13][14][15] The patient in question denied having used any other topical or systemic facial medication at that time with the exception of interferon, which she was taking to treat multiple sclerosis.…”

Section: Multiple Sclerosis (Ms) Is a Chronic Demyelinating Disease Omentioning

confidence: 99%

Erupção acneiforme aguda induzida por interferon beta-1b durante tratamento para esclerose múltipla

Rosa

Matias

Cedrim

et al. 2011

An. Bras. Dermatol.

View full text Add to dashboard Cite

Abstract:Multiple sclerosis is an inflammatory demyelinating disease of presumed autoimmune origin that affects the central nervous system. The main form of therapy is based on the use of immunomodulators such as interferon beta, which are usually well tolerated. Skin manifestations resulting from treatment with interferon beta-1b consist principally of reactions at the site of subcutaneous application of the drug. The present case report describes a female patient who developed an acneiform eruption resulting from treatment with interferon beta-1b. Keywords: Acneiform eruptions; Interferon-beta; Multiple sclerosis; Therapeutics Resumo: Esclerose múltipla é uma doença inflamatória desmielinizante, com presumida origem autoimune, que afeta o sistema nervoso central. A principal modalidade terapêutica é baseada no uso de imunomoduladores, como o interferon beta, que são geralmente bem tolerados. As manifestações cutâneas secundárias ao interferon beta-1b são representadas, na maioria das vezes, por reações no local de sua aplicação subcutânea. Descrevemos o caso de uma paciente do sexo feminino que desenvolveu um quadro de erupção acneiforme pelo interferon beta-1b.

show abstract

“…Some years ago, Wollenberg et al [14] proposed a scoring tool for the erythematous papulopustular rash, which is calculated by evaluating the body involvement, facial involvement, and clinical grading of the skin items. This is suitable for monitoring the severity of the most common AEs from EGFRIs, but not for the whole cutaneous toxicity.…”

Section: Introductionmentioning

confidence: 99%

The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): A New Tool for Grading and Managing Skin Adverse Reactions to Epidermal Growth Factor Receptor Inhibitors

Lisi

Bellini²,

Bianchi³

2014

Oncology

View full text Add to dashboard Cite

Background: Skin toxicity is frequent and debilitating in oncologic patients treated with epidermal growth factor receptor inhibitors (EGFRIs). Grading and management of skin adverse events (AEs) are poorly standardized. Materials and Methods: We developed a new score (EGFRISTI: Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index) which is able to quantify and monitor all EGFRI-related dermatologic AEs over time. The utility of this tool was validated in 130 patients treated with 5 different EGFRIs including both monoclonal antibodies and tyrosine kinase inhibitors. Results: The mean baseline EGFRISTI score was 26.9 (range: 6.0-64.5). Mild toxicity was found in 55 patients (42.3%), moderate toxicity in 43 (33.1%), and severe toxicity in 32 patients (24.6%). After the first-line toxicity treatment, an EGFRISTI score reduction of >75% was obtained in 31 patients (34.1%) and one of 50% in 40 patients (43.9%), while an improvement of <50% was observed in the remaining 20 subjects (22.0%). Conclusions: The EGFRISTI is a simple and reliable tool to quantify and express the severity of all clinical signs and symptoms of EGFRI skin toxicity with a single numerical value, to choose the most suitable therapy, and to measure its efficacy.

show abstract

A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition

Cited by 39 publications

References 6 publications

Management of EGFR-inhibitor associated rash: A retrospective study in 49 patients

Management of EGFR-inhibitor associated rash: A retrospective study in 49 patients

Erupção acneiforme aguda induzida por interferon beta-1b durante tratamento para esclerose múltipla

The Epidermal Growth Factor Receptor Inhibitor-Related Skin Toxicity Index (EGFRISTI): A New Tool for Grading and Managing Skin Adverse Reactions to Epidermal Growth Factor Receptor Inhibitors

Contact Info

Product

Resources

About